Description
Added on the 16/12/2020 13:00:00 - Copyright : EFE Inglés
Laupheim (Germany), Feb 4 (EFE / EPA), (Camera: Ronald Wittek).- The biopharmaceutical company Rentschler Biopharma is working on the production of CureVac's first generation Covid-19 vaccine CVnCoV, which is currently in phase II and III of the clinical trial. FOOTAGE OF RENTSCHLER BIOPHARMA HEADQUARTERS IN LAUPHEIM, GERMANY.
Bangkok (Thailand), Apr 7 (EFE / EPA).- A laboratory at the University of Chulalongkorn in Bangkok, is working on a prototype of a vaccine against Covid-19 developed mainly from tobacco leaves.The locally-made anti-coronavirus vaccine developed by a Thai firm Baiya Phytopharm called Baiya SARs-CoV-2 Vax 1, which was produced with proteins from tobacco leaves, has now gone through a process to be used in human trials after the tests on animals proved effective. (Camera: RUNGROJ YONGRIT)SHOT LIST: THE UNIVERSITY LABORATORY PRODUCING THE COVID-19 VACCINE PROTOTYPE IN BANGKOK, THAILAND.
Beirut, Lebanon, Feb 16 (EFE/EPA) - (Camera: Nabil Mounzer) Lebanese medical personnel received the Pfizer-BioNTech covid-19 vaccine Tuesday during a nationwide vaccination campaign. In total, twenty-eight thousand doses of the Pfizer-BioNTech vaccine arrived in Lebanon on February 13. The first doses will be targeted to the elderly and health care workers according to the order of high-risk groups.FOOTAGE OF MEDICAL PERSONNEL BEING VACCINATED IN LEBANON.
Marburg (Germany), Feb 10 (EFE / EPA).- The pharmaceutical company BioNtech produces its coronavirus vaccine in its headquarters in Marburg, Germany. FOOTAGE OF THE EXTERIOR OF BIONTECH HEADQUARTERS IN MARBURG, GERMANY.
Berlin (Germany), Feb 1 (EFE / EPA), (ARCHIVE).- The German company BioNTech announced Monday that it will supply the EU with 75 million doses of its Covid-19 vaccine in the second quarter of the year after optimizing its production process. ARCHIVE FOOTAGE OF BIONTECH HEADQUARTERS IN MAINZ AND VACCINATION CAMPAIGN IN STUTTGART, GERMANY.